ARCT vs. IMCR, ANIP, DYN, INDV, AMPH, ARDX, EVO, ETNB, OCUL, and GPCR
Should you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Immunocore (IMCR), ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), Ocular Therapeutix (OCUL), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.
Arcturus Therapeutics vs.
Arcturus Therapeutics (NASDAQ:ARCT) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.
Arcturus Therapeutics has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Immunocore has a net margin of -15.87% compared to Arcturus Therapeutics' net margin of -36.39%. Immunocore's return on equity of -12.84% beat Arcturus Therapeutics' return on equity.
Arcturus Therapeutics received 376 more outperform votes than Immunocore when rated by MarketBeat users. However, 73.68% of users gave Immunocore an outperform vote while only 66.27% of users gave Arcturus Therapeutics an outperform vote.
In the previous week, Immunocore had 6 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 9 mentions for Immunocore and 3 mentions for Arcturus Therapeutics. Immunocore's average media sentiment score of 1.42 beat Arcturus Therapeutics' score of 0.27 indicating that Immunocore is being referred to more favorably in the news media.
Arcturus Therapeutics currently has a consensus target price of $59.20, suggesting a potential upside of 363.59%. Immunocore has a consensus target price of $65.64, suggesting a potential upside of 123.86%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcturus Therapeutics is more favorable than Immunocore.
94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 15.3% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 9.1% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Arcturus Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.
Summary
Immunocore beats Arcturus Therapeutics on 10 of the 19 factors compared between the two stocks.
Get Arcturus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcturus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ARCT) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy ARCT Stock Free ARCT Stock Alerts